Comparison of self-reported female condom failure and biomarker-confirmed semen exposure.


Journal

Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361

Informations de publication

Date de publication:
11 2019
Historique:
received: 19 12 2018
revised: 20 07 2019
accepted: 24 07 2019
pubmed: 6 8 2019
medline: 10 7 2020
entrez: 6 8 2019
Statut: ppublish

Résumé

To investigate whether rates of self-reported Woman's Condom (WC) clinical failure and semen exposure from a functionality study are comparable to results from a contraceptive efficacy substudy. We structured our comparative analysis to assess whether functionality studies might credibly supplant contraceptive efficacy studies when evaluating new female condom products. Couples not at risk of pregnancy in the functionality (breakage/slippage/invagination/penile misdirection) study and women in the contraceptive efficacy study completed condom self-reports and collected precoital and postcoital vaginal samples for up to four uses of the WC. Both studies used nearly identical self-report questions and the same self-sampling procedures and laboratory for prostatic specific antigen (PSA), a well-studied semen biomarker. We compared condom failure and semen exposure proportions using generalized estimating equations methods accounting for within-couple correlation. Ninety-five (95) efficacy substudy participants used 334 WC and 408 functionality participants used 1572 WC. Based on self-report, 19.2% WC (64 condoms) clinically failed in the efficacy substudy compared to 12.3% WC (194 condoms) in the functionality study (p=.03). Of the 207 WC efficacy uses with evaluable postcoital PSA levels, 14.5% (30 uses) resulted in semen exposure compared to 14.2% (184 uses) of the 1293 evaluable WC functionality study uses. When evaluating the ability of an experimental condom to prevent semen exposure, the rate of clinical condom failure reported by participants risking pregnancy in an efficacy substudy was significantly higher than the rate reported by participants not risking pregnancy in a functionality study. The rate of semen exposure, assessed by an objective biomarker was nearly identical for the two studies. Our results suggest that an objective marker of semen exposure in functionality studies could provide a reasonable alternative to contraceptive efficacy studies in evaluating risk of unintended pregnancy and inferring protection from sexually transmitted infection than condom failure rates based on self-report.

Identifiants

pubmed: 31381878
pii: S0010-7824(19)30371-3
doi: 10.1016/j.contraception.2019.07.143
pmc: PMC6875637
mid: NIHMS1539269
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Banques de données

ClinicalTrials.gov
['NCT01223313', 'NCT01178840']

Types de publication

Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

406-412

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : PEPFAR
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

J Womens Health (Larchmt). 2014 Oct;23(10):787-91
pubmed: 25268551
Sex Transm Dis. 1998 Sep;25(8):427-32
pubmed: 9773437
Contraception. 2007 Jun;75(6):407-19
pubmed: 17519146
Contraception. 2005 Feb;71(2):130-6
pubmed: 15707563
Am J Epidemiol. 2003 Feb 15;157(4):282-8
pubmed: 12578797
Contraception. 1999 Nov;60(5):289-98
pubmed: 10717781
Hum Reprod. 2008 Nov;23(11):2444-51
pubmed: 18664473
Contraception. 2014 Feb;89(2):134-8
pubmed: 24314911
Contraception. 2003 Feb;67(2):139-50
pubmed: 12586324
Contraception. 2013 Dec;88(6):749-57
pubmed: 24028752
Am J Epidemiol. 2003 Feb 15;157(4):289-97
pubmed: 12578798
Sex Transm Dis. 2007 Aug;34(8):557-62
pubmed: 17417133
Contraception. 2009 May;79(5):339-44
pubmed: 19341844
Am J Clin Pathol. 2008 Jun;129(6):952-8
pubmed: 18480013
Sex Transm Dis. 2006 Aug;33(8):476-9
pubmed: 16865047
Contraception. 2017 Nov;96(5):336-343
pubmed: 28711645
Fed Regist. 2018 Sep 27;83(188):48711-3
pubmed: 30272398
Am J Epidemiol. 2007 Jul 1;166(1):88-96
pubmed: 17420182
Contraception. 2012 Jul;86(1):55-61
pubmed: 22386229
Clin Chem. 2006 Aug;52(8):1568-74
pubmed: 16762996
Clin Chem. 1992 Nov;38(11):2341-3
pubmed: 1385021
Contraception. 1999 Mar;59(3):195-201
pubmed: 10382083
Contraception. 2007 Apr;75(4):251-5
pubmed: 17362701

Auteurs

Terri L Walsh (TL)

Essential Access Health (formerly California Family Health Council), 3600 Wilshire Blvd., Ste. 600, Los Angeles, CA 90010. Electronic address: twalsh@essentialaccess.org.

Margaret C Snead (MC)

Division of Reproductive Health, Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, GA 30333.

Breione J St Claire (BJ)

Essential Access Health (formerly California Family Health Council), 3600 Wilshire Blvd., Ste. 600, Los Angeles, CA 90010.

Jill L Schwartz (JL)

CONRAD/EVMS, 1911 N. Fort Myer Drive, Ste. 900, Arlington, VA 22209.

Christine K Mauck (CK)

CONRAD/EVMS, 1911 N. Fort Myer Drive, Ste. 900, Arlington, VA 22209.

Ron G Frezieres (RG)

Essential Access Health (formerly California Family Health Council), 3600 Wilshire Blvd., Ste. 600, Los Angeles, CA 90010.

Diana L Blithe (DL)

Contraceptive Development Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6710B Rockledge Dr, Bethesda, MD 20817.

David F Archer (DF)

Obstetrics & Gynecology, Eastern Virginia Medical School, PO Box 1980, Norfolk, VA 23501.

Kurt T Barnhart (KT)

University of Pennsylvania Medical Center, 3701 Market St., Ste. 800, Philadelphia, PA 19104.

Jeffrey T Jensen (JT)

Department of Obstetrics & Gynecology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239.

Anita L Nelson (AL)

Essential Access Health (formerly California Family Health Council), 3600 Wilshire Blvd., Ste. 600, Los Angeles, CA 90010.

Michael A Thomas (MA)

Department of Obstetrics & Gynecology, University of Cincinnati Medical Center, 234 Goodman St., Cincinnati, OH 45219.

Livia S Wan (LS)

Department of Obstetrics & Gynecology, New York University,462 First Ave., New York, NY 10016.

Mark A Weaver (MA)

Department of Mathematics and Statistics, Elon University, Elon, NC 27244.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH